Following its latest setback, Achillion posts some encouraging PoC data for lead drug
Five months after taking a hit on its decision to shelve a mid-stage program for their lead therapy as a monotherapy for paroxysmal nocturnal hemoglobinuria, Achillion $ACHN is back with more encouraging proof-of-concept data for the drug as a therapy for the anemia that can beset patients taking the industry standard drug Soliris.
Investigators say they tracked a sharp drop in the need for transfusions among Soliris patients suffering from anemia. The group needed just 1 transfusion with 2 units of blood during the 24-week study period, compared to the 34 transfusions and 58 units needed in the 24 weeks before they began treatment with the add-on therapy. They also noted increases in mean hemoglobin of approximately 2 g/dL at week 4 (n=11).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.